Order Article Reprints

Awada G, Schwarze JK, Tijtgat J, Fasolino G, Everaert H, Neyns B. A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS^Q61R/K/L Mutant Melanoma (TraMel-WT). Cancers. 2021; 13(9):2010. https://doi.org/10.3390/cancers13092010

Awada, Gil, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, and Bart Neyns. 2021. "A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS^Q61R/K/L Mutant Melanoma (TraMel-WT)" Cancers 13, no. 9: 2010. https://doi.org/10.3390/cancers13092010

Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Everaert, H., & Neyns, B. (2021). A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS^Q61R/K/L Mutant Melanoma (TraMel-WT). Cancers, 13(9), 2010. https://doi.org/10.3390/cancers13092010